In brief: Select Vaccines, Psiron, Visiomed

By Graeme O'Neill
Thursday, 21 April, 2005

Select Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs

Psiron (ASX:PSX) has presented new data at a US medical conference confirming the anti-cancer effect in in vitro trials of its Coxsackievirus A21 virotherapy in cancer cell lines for breast, prostate and colon cancer and multiple myeloma.

Visiomed (ASX:VSG) subsidiary InfaMed has begun to sell its Funhaler children's asthma spacer device in Australian pharmacies.

Content from other channels on our network

The Data-Ready Foundation for an AI-Powered Healthcare Future

Innovating chemical dosing & dilution in aged care

A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections

The rise of non-clinical, community-led safe spaces: how lived experience is reshaping suicide prevention

Mandatory VR violence training for nursing students

Indigenous food culture and responsible seafood celebrated

Shaking up whey protein manufacturing technique

Danone to acquire Made Group

Five trends tracked for NZ's fresh produce sector

Poultry and egg producers in lockdown as avian flu detected in WA

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens

Accenture acquires Dragos and increases OT cybersecurity offering

GWW to provide recycled water for a Victorian data centre

Valves, data centres and the invisible infrastructure of Australian industry

In brief: Select Vaccines, Psiron, Visiomed

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network